- Company
- The export performance of biopharma is up
- by Kim, Jin-Gu Sep 10, 2024 05:48am
- The export performance of two out of three pharmaceutical and biotech companies is reported to have increased year-over-year (YoY). The total export sales of 24 companies increased from KRW 3.6869 trillion to KRW 4.8975 trillion over the year, up 33%. In particular, the export performance of Samsung Biologics, Celltrion, and SK Biopharm
- Company
- MS drug development poses a big challenge for pharma
- by Son, Hyung-Min Sep 10, 2024 05:48am
- Pharmaceutical companies based in South Korea and overseas are having difficulties developing new drugs for multiple sclerosis. Sanofi failed to demonstrate the drug's efficacy in some parts of clinical trials, and Merck's Phase 3 clinical trial did not meet primary endpoints. However, Sanofi announced that it will attempt to receive approv
- Company
- CAR-T cell therapy Yescarta expected to enter the KOR market
- by Eo, Yun-Ho Sep 10, 2024 05:48am
- Another new CAR-T cell therapy 'Yescarta' is anticipated to enter the Korean market. The Ministry of Food and Drug Safety (MFDS) recently posted that it has designated an orphan drug for Gilead Sciences' Yescarta (axicabtagene ciloleucel). The designated indication will include ▲Adult patients with relapsed or refractory diffuse lar
- Company
- Is the heyday of domestic flu vaccines coming to an end?
- by Moon, sung-ho Sep 10, 2024 05:48am
- Competition among pharmaceutical and biotech companies with influenza (flu) vaccines is intensifying more than ever. As more and more companies, including global pharmaceutical companies, are seeking to supply vaccines on-site, and specialized vaccines are being launched for each age group, the competition is expected to be unprecedented thi
- Company
- Livtencity's introduction raises expectations in the field
- by Hwang, Byung-woo Sep 10, 2024 05:47am
- The introduction of Livtencity (maribavir), a drug that can be prescribed to manage infections in transplant patients following the use of existing treatments, has been met with positive reviews in the field due to a lack of treatment options. Although the actual number of patients who will be prescribed the drug is limited, the drug is expec
- Company
- Eliquis generics to enter and reshape DOAC mkt in SEP
- by Moon, Sung-ho Sep 10, 2024 05:47am
- From this month (September), numerous generic drugs will be released in the direct-acting oral anticoagulant (DOAC) market. Following Bayer's Xarelto (rivaroxaban), Pfizer and BMS's Eliquis (apixaban) is also facing its patent expiry. According to industry sources on the 26th, the Ministry of Health and Welfare recently prepared a notic
- Company
- Hugel hosts Train-The-Trainer seminar for global medical aes
- by Kwon Sung-Yong Sep 9, 2024 09:45am
- Hugel Inc., a leading global medical aesthetics company, said on Monday it hosted the Train-The-Trainer program at the end of August with medical experts from overseas to improve their knowledge and practices of skin rejuvenation. Some 20 medical practitioners from nine countries, including the US, Australia, Canada, China, Taiwan, Japan, Ind
- Company
- 'Vabysmo' likely to receive approval for third indication
- by Eo, Yun-Ho Sep 9, 2024 05:49am
- 'Vabysmo,' the first bispecific antibody for the treatment of ophthalmologic disease, is under review for expanded indication for retinal vein occlusion (RVO) in South Korea. According to industry sources, Roche Korea has applied for expanded approval of Vabysmo (faricimab) from the Ministry of Food and Drug Safety (MFDS). The drug receiv
- Company
- Jassen’s Balversa can be prescribed in general hospitals
- by Eo, Yun-Ho Sep 9, 2024 05:49am
- The new bladder cancer drug Balversa may now be prescribed in general hospitals in Korea. According to industry sources, Janssen Korea’s FGFR-inhibiting urothelial carcinoma (bladder cancer) drug Balversa (erdafitinib) has recently passed the drug committees (DCs) of tertiary hospitals including Seoul St. Mary's Hospital, Seoul Asan Medi
- Company
- Vonjo receives orphan drug designation in Korea
- by Eo, Yun-Ho Sep 6, 2024 05:48am
- The oral myelofibrosis drug Vonjo has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety announced so on the 3rd through an orphan drug designation. Specifically, the drug is indicated for ‘adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythem
